BioSpace News Archive

Asunercept Plus Radiotherapy Significantly Prolongs Time to Deterioration of Quality of Life Compared to Radiotherapy Alone in Patients with Recurrent Glioblastoma

Bridge Therapeutics Inc. announced that it has received feedback from the Food and Drug Administration from a Pre-Investigational New Drug meeting for the development of BT-219, a therapy to treat Opioid Dependence.

Brown University and Hebrew SeniorLife leading research incubator

Collaboration aims to evaluate the potential of microbiome-derived antigens that mimic tumor antigens and neoantigens (“onco-mimics”) to induce anti-tumor immune responses

Maryland, MD: Syngene, a world-leading manufacturer of image analysis solutions, is pleased to announce it has entered a sponsorship agreement with Tufts Launchpad | BioLabs developed by Tufts University to be Boston’s premier fully equipped, co-working and shared lab space for biotech start-ups.

Genedata Selector® deployed to streamline complex cell line development processes

Generates over USD 1 million in sales through new POCare platform

Polarean Imaging plc, the medical-imaging technology company, with a proprietary magnetic resonance imaging (MRI) drug-device combination, announces that the enrolment for its Phase III non-inferiority clinical trials (the “Clinical Trials”) is now complete for both the lung transplant pathway and the lung resection pathway.

As part of the European Union’s “Horizon 2020" research program, Evonik and nine project partners from five countries have succeeded in developing a novel new reactor for catalysing OXO reactions, which is 70% more energy efficient.

The Company reaffirms that it will file for the lurbinectedin NDA to the FDA under accelerated approval regulations for the treatment of relapsed Small Cell Lung Cancer (SCLC) during the fourth quarter (Q4) of 2019.